TRADITIONAL CHINESE MEDICINE COMBINED WITH HORMONE THERAPY TO TREAT PREMATURE OVARIAN FAILURE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS by Kou, Mei-Jing et al.
Kou et al., Afr J Tradit Complement Altern Med. (2016) 13(5):160-169 
doi:10.21010/ajtcam.v13i5.21 
160 
 
TRADITIONAL CHINESE MEDICINE COMBINED WITH HORMONE THERAPY TO TREAT 
PREMATURE OVARIAN FAILURE: A META-ANALYSIS OF RANDOMIZED CONTROLLED 
TRIALS 
 
Mei-Jing Kou1,2, Xiu-Fang Ding1, Jia-Xu Chen1,2*, Yan Liu2, Yue-Yun Liu1 
 
1  School of  Basic Medical Science, Beijing University of Chinese Medicine, Beijing 
100029, China. 2 School of Pre-clinical Medicine, Hubei University of Chinese Medicine, Wuhan  430061, 
China 
 
The first two authors contributed equally to this work. 
 
*Corresponding author: Dr. Jia-Xu Chen, E-mail: chenjiaxu@hotmail.com 
 
 
Abstract  
 
Background: This meta-analysis aimed to provide critically estimated evidence for the advantages and disadvantages of Chinese 
herbal medicines used for premature ovarian failure (POF), which could provide suggestions for rational treatments. 
Materials and Methods: The databases searched included MEDLINE, EMBASE, CNKI, VIP, China Dissertation Database, China 
Important Conference Papers Database, and online clinical trial registry websites. Published and unpublished randomized controlled 
trials of traditional Chinese medicine (TCM) combined with hormone therapy (HT) and HT alone for POF were assessed up to 
December 30, 2015. Two authors extracted data and assessed trial quality independently using Cochrane systematic review methods. 
Meta-analysis was used to quantitatively describe serum hormone levels and Kupperman scores associated with perimenopause 
symptoms.  
Results: Seventeen randomized controlled trials involving 1352 participants were selected. Compared with HT alone, although no 
significant effects were observed in the levels of luteinizing hormone, therapy with TCM combined with HT compared to HT alone 
effectively altered serum hormone levels of follicle stimulating hormone (P<0.01) and estradiol (P < 0.01), and improved 
Kupperman index scores (P< 0.01). 
Conclusions: The reported favorable effects of TCM combined with HT for treating POF patients are better than HT 
alone.However,the beneficial effects derived from this combination therapy cannot be viewed conclusive.In order to better support 
the clinical use, more rigorously designed trials are required to provide. 
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Introduction 
 
Premature ovarian failure (POF) is characterized by the cessation of the menstrual cycle, sustained amenorrhea, atrophy of 
sex organs, and accompanied by increased levels of follicle stimulating hormone (FSH) and luteinizing hormone (LH) and decreased 
levels of estrogen (E2) before the age of 40 years in women whose secondary sexual characteristics have developed normally and 
regular menstruation had been established (Kalantaridou et al., 1998). 
There is currently no definitive and effective therapy for treating POF. Symptomatic treatment is primarily used, such as 
hormone therapy (HT), ovulation induction, immunosuppressive therapy, and oocyte donation (Altuntas et al., 2006). Estrogen-
progestin replacement therapy can rapidly improve premenopausal symptoms that are caused by low estrogen status. Additionally, 
estrogen therapy (ET) can achieve short-term therapeutic effects by promoting the development of the uterus, hypertrophy and 
hyperplasia in uterine smooth muscle cells, the uterine muscular layer thickness, thickness of the endometrium, and increasing the 
uterine blood flow. Thus, it can effectively prevent uterine atrophy; however, it cannot improve ovarian function or promote 
follicular development and ovulation rates. Therefore, long-term ET is required due to a failure to restore normal ovarian endocrine 
function. Surprisingly, these long-term ET have also increased the risk of endometrial cancer and breast cancer, especially a higher 
occurrence of breast cancer (Woad et a1., 2013).Another study showed that HT for < 4 years incurred a relatively low risk, whereas 
this risk may increase with therapy of over 4 years. Thus, individual assessments must be done at least once each year to decide 
whether to continue this treatment (Van and Schoemaker, 1999). As a result, this strategy results in a low clinical compliance. 
Traditional Chinese medicine (TCM) have been used for thousands of years, and are still commonly used to treat people 
who suffer from different diseases in Southeast Asian countries. According to the TCM theory, there is a unique herbal formulation 
for each syndrome or symptom, thus, formulations or prescriptions must be adapted by adding or subtracting herbs. For complex 
diseases in China, the diagnostic paradigms of Western medicine are often used for herbal medicines without applying TCM theory 
(Poll, 2005). An essential feature of integrated traditional Chinese and Western medicine for treating diseases involves fasting cures, 
changes in dietary habits, and so on (Dobos  and Tao,2011). However, the levels of evidence are lower (Rakel, 2012). 
The current literature indicates that herbal medicines are being used for POF in China. To increase the therapeutic efficacy, 
shorten recovery time, and reduce any side effects, combination treatments with Western medicines plus herbal medicines are 
selected to treat POF (Chao et al., 2003).Current research suggests that a combination of a TCM with HT, if used correctly, can not 
only shorten the treatment time, improve efficacy, and reduce the side effects of long-term use of hormones, but can also promote the 
recovery of ovarian function and menstruation. 
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As described above, this method is safe, economic, effective, and worthy of clinical application. However, the related 
clinical research studies on these combination therapies were done independently and only involved small sample sizes. Therefore, 
in this study, we conducted a meta-analysis for the purpose of providing rational treatment evidence for POF based on a TCM 
combined with HT. 
A PRISMA checklist is available as supporting information for study selection (Figure 1).  
 
 
 Materials and Methods 
Search Methods and Study Selection  
 
The medical literature up to December 30, 2015 was searched in the following databases: MEDLINE, EMBASE, Chinese 
National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP), China Dissertation Database, China 
Important Conference Papers Database, and online clinical trial registry websites and the Cochrane library. The search terms used 
included “premature ovarian failure,” “traditional Chinese herbal medicine,” “hormone therapy,” “clinical trial,” and “randomized 
controlled trials.” 
Two authors independently performed literature searches, study selection, and data extraction. Data extracted from selected papers 
included authors, paper title, publication year, study size, age of subjects, information on methodology used, name of  a Chinese herb, 
course of treatment, treatment measures for a control group, and outcomes and adverse events. Any disagreement was resolved by a 
discussion and reached a consensus with the third party (JXC).  
 
Inclusion and Exclusion Criteria  
 
Studies were included if they met all the following criteria:(i) The purpose of article is to study on clinical effect of TCM 
combined with HT compared with HT alone for POF patients;(ii) The primary efficacy variable including serum hormone and some 
clinical symptoms such as hectic fever, night sweats, emotional depression, vaginal dryness and decreased libido; and (iii) Included 
studies must be clearly record the mean and standard deviation which related to studies. The studies with non-RCTs were excluded；
multiple journals that reported on the same groups of subjects were also excluded. Literature searches were conducted for two 
languages: English and Chinese. 
 
Trial Quality Assessment  
 
Two authors (MJK, YL) assessed the quality of all the included studies. The quality of the included RCTs qualities was 
assessed based on Jadad scores(Jadad and Moore.1996).The methods used were: randomization (appropriate: 2 points; unclear: 1 
point; inappropriate: 0 points); concealment of allocation (appropriate: 2 points; unclear: 1 point; inappropriate: 0 points); double 
blinding (double blinding and description: 2 points; double blinding and description was unclear: 1 point; no blinding or no 
description: 0 points); and withdrawals and dropouts (description: 1 point; no description: 0 points). The scores ranged from 1 to 7 
points, with scores of 1-3 categorized as poor-quality studies and 4-7 as high-quality studies. 
 
Data Analysis 
 
Data were analyzed using RevMan 5.0 software. Data were summarized using the standardized mean difference (SMD) 
along with the corresponding 95% CI for continuous outcomes. Meta-analysis was used if trials had a good homogeneity with regard 
to study design, control, participants, interventions, and outcome measures; this was evaluated by determining the I2 value. The 
quality component of the methodology was used, including generation of an allocation sequence, double blinding, and concealment 
of allocation. For publication bias, funnel plot analysis was explored. 
 
 
Results 
Included Studies 
 
Figure 1 is a flowchart for our search procedures and trial selection. After a thorough literature search using six databases, 
a total of 364 publications were identified, 289 of which were excluded after screening their titles and abstracts. A total of 75 full-
text papers were retrieved, and finally, a total of 17 studies were included in our meta-analysis (Feng and Li, 2013; Gao and Bi,2008; 
Han et al.,2008;Jin et al.,2013; Li and Peng, 2009; Liu et al., 2009; Li , 2009; Lu, 2009; Qi et al., 2008; Qin,2006; Yi et al., 2008; 
Zhang, 2008; Zhu and Xie, 2012; Yang and Shen, 2015; Liu,2015; Lu,2014; Jin, 2015). The details for these included studies are 
listed in Table 1. 
All included studies were evaluated using a graded scale, and the methodological quality of most included papers was 
assessed as poor. Randomized allocation of individuals was described in all studies; however, only six trials described the methods 
used for sequence generation, including a random number table (Gao and Bi, 2008;Jin et al.,2013; Liu et al.,2009; Zhang,2008; Zhu 
and Xie,2012; Yang and Shen,2015).Because of insufficient information provided for randomization methods, we could not 
accurately judge whether or not studies were conducted properly. Both allocation concealment and double-blinding were not used for 
all trials. Only three trials reported follow-ups, drop-outs, or withdrawals (Gao and Bi, 2008; Li and Peng, 2009; Yi et al., 2008). 
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Figure 1: Flow diagram of activity 
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General Characteristics of the Included Trials 
      
 Six of the 13 trials used medroxyprogesterone acetate (MPA) and conjugated equine estrogens (CEE) for hormone control 
therapy, three used MPA and estradiol valerate (EV), and one used MPA and diethylstilbestrol (DES); three used EV and ethinyl 
estradiol-cyproterone acetate (EE-CA). The general characteristics of the included studies are shown in Table 1 (Sackett et al.,1996; 
Sackett and Wennberg,1997；Rakel D, 2012；Chao et al., 2003; Jadad and Moore. 1996; Feng and Li, 2013; Gao and Bi, 2008; 
Han et al., 2008;Jin et al., 2013; Li and Peng, 2009; Liu et al., 2009; Li, 2009; Lu, 2009; Qi et al., 2008; Qin,2006; Yi et al., 2008; 
Zhang, 2008; Zhu and Xie, 2012; Yang and Shen, 2015; Liu, 2015;  Lu, 2014; Jin, 2015). 
Table 1: Study characteristics of the included randomized controlled trials 
 Time (months) 
N 
(TCHM/HT) Hormones/Drugs 
Traditional Chinese 
medicines 
Feng and Li 
2013 5 33/32 estradiol valerate, dydrogesterone Peikun pills 
Gao and Bi 
2008 3 32/31 conjugated estrogen, medroxyprogesterone acetate 
Ziyinshugan 
decoction 
Han et al. 
2008 3 58/58 Diethylstilbestrol, medroxyprogesterone acetate 
kangluanshuai 
granules 
Jin et al. 
2013 6 91/88 conjugated estrogen, medroxyprogesterone acetate 
Bushenhuoxue 
decoction 
Li and Peng 
2009 3 36/32 estradiol valerate, medroxyprogesterone acetate 
Yijing 
decoction 
Liu et al. 2009 3 24/22 estradiol valerate, estradiol cyproterone Yishenkangshuai decoction 
Li and Wu 
2009 3 18/18 estradiol valerate, medroxyprogesterone acetate Yishen decoction 
Lu 2009 3 37/30 conjugated estrogen, medroxyprogesterone acetate Modified erxian decoction 
Qi et al. 
2008 3 26/26 estradiol valerate, medroxyprogesterone acetate 
Yishenfuchao 
decoction 
Qin 
2006 3 35/37 conjugated estrogen, medroxyprogesterone acetate 
Yishen 
decoction 
Yi et al. 
2008 3 21/20 conjugated estrogen, medroxyprogesterone acetate 
Tiaojingkangshuai 
decoction 
Zhang 
2008 6 30/28 conjugated estrogen, medroxyprogesterone acetate 
Qingrehuoxue 
decoction 
Zhu and Xie 
2012 3 21/21 estradiol valerate, estradiol cyproterone 
Bushentiaochong 
decoction 
Yang and 
Shen 2015 3 92/95 estradiol valerate, medroxyprogesterone acetate 
Bushentiaochong 
decoction 
Liu2015 6 30/30 Estradiol and progesterone tablets Kuntai decoction 
Lu2014 3 30/30 estradiol valerate, medroxyprogesterone acetate Bushenyangxue decoction 
Jin2015 3 70/70 estradiol valerate, medroxyprogesterone acetate Gushentiaochong decoction 
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Methodological Quality of the Included Trials 
 
Eight of the 17 RCTs did not describe the randomization method used, and six used a random number table, although 
random allocation was unconcealed and it was not specified whether a blinding method was used. Three RCTs described follow-ups 
and drop-outs. Overall, 14 RCTs were assessed as being of poor quality. The results of the quality assessments for the included 
studies are shown in Table 2(Feng and Li, 2013; Gao and Bi,2008; Han et al.,2008;Jin et al.,2013; Li and Peng,2009; Liu et al.,2009; 
Li ,2009; Lu,2009; Qi et al., 2008; Qin,2006; Yi et al.,2008;Zhang,2008; Zhu and Xie,2012; Yang and Shen,2015; Liu,2015; 
Lu,2014; Jin,2015). 
 
Table 2: Quality assessments of the included randomized controlled trials 
Study ID Sequence generation 
Allocation 
concealment 
Blinding 
 
Attrition and 
Dropout score 
Feng and Li 
2013 Unclear Unclear No Yes 1 
Gao and Bi 
2008 Appropriate Unclear No No 2 
Han et al. 
2008 Unclear Unclear No No 1 
Jin et al. 
2013 Appropriate Unclear No Yes 3 
Li and Peng 
2009 Unclear Unclear No No 1 
Liu et al. 2009 Unclear Unclear No No 1 
Li and Wu 
2009 Unclear Unclear No No 1 
Lu 2009 Unclear Unclear No No 1 
Qi et al. 
2008 Unclear Unclear No No 1 
Qin 
2006 Appropriate Unclear No No 2 
Yi et al. 
2008 Appropriate Unclear No Yes 3 
Zhang 
2008 Appropriate Unclear No No 2 
Zhu and Xie 2012 Unclear Unclear No No 1 
Yang and Shen 
2015 Appropriate Unclear No No 2 
      Liu2015 Unclear Unclear No No 1 
Lu2014 Unclear Unclear No No 1 
Jin2015 Unclear Unclear No No 1 
 
 
Publication Bias 
 
Funnel plots analysis of the 13 trials on FSH, LH, E2 were conducted to investigate the publication bias. It demonstrated 
symmetry, suggesting no potential publication bias (Figure 2). 
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Effect Estimates 
Comparisons of   Serum Hormones Levels (FSH, LH, and E2) 
 
FSH: All 17 studies included comparisons of the effects on serum FSH levels in patients with POF after treatment with a TCM 
combined with HT and HT alone. Our meta-analysis results are shown in Figure 3 (Feng and Li, 2013; Gao and Bi,2008; Han et 
al.2008;Jin et al.,2013; Li and Peng,2009; Liu et al.,2009; Li , 2009; Lu,2009; Qi et al.,2008; Qin,2006; Yi et 
al.2008;Zhang,2008;Zhu and Xie,2012; Yang and Shen,2015; Liu,2015; Lu,2014; Jin,2015).Treatment with a TCM combined with 
HT was significantly superior compared with that of HT alone for reducing FSH levels (SMD: -7.08, 95% CI: -9.80,-4.37, 
P<0.00001).  
 
Study or Subgroup
Feng and Li2013
Gao and Bi2008
Han et al.2008
Jin 2015
Jin et al.2013
Li and Peng2009
Li and Wu2009
Liu 2015
Liu et al.2009
Lu 2014
Lu2009
Qi et al.2008
Qin 2006
Yang and Shen 2015
Yi et al.2008
Zhang 2008
Zhu and Xie 2012
Total (95% CI)
Heterogeneity: Tau² = 19.91; Chi² = 72.88, df = 16 (P < 0.00001); I² = 78%
Test for overall effect: Z = 5.11 (P < 0.00001)
Mean
41.5
33.56
31.6
21.57
16.53
36.5
47.5
37.3
40.46
22
39.3
40.5
40.55
28.47
46.1
40.34
33.57
SD
6.8
13.55
12.8
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20.2
11.23
8.95
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32
58
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24
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Mean
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30.15
18.56
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56.78
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40.34
41.6
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17.33
13.1
13.52
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18.36
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Total
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Weight
8.3%
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9.4%
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-23.43 [-31.13, -15.73]
-8.40 [-13.11, -3.69]
-8.58 [-12.75, -4.41]
-2.03 [-3.47, -0.59]
-4.80 [-16.66, 7.06]
-9.28 [-20.09, 1.53]
-10.30 [-21.18, 0.58]
0.12 [-9.06, 9.30]
0.00 [-6.58, 6.58]
-0.90 [-10.75, 8.95]
-12.28 [-20.34, -4.22]
-12.34 [-19.19, -5.49]
-9.43 [-11.96, -6.90]
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Figure 3: Comparisons of treatment efficacy between traditional Chinese medicine combined with hormone therapy and hormone 
therapy alone on FSH levels. 
 
LH: Fifteen trials compared the effects on serum LH levels in patients with POF after treatment with a TCM combined with HT and 
HT alone (Gao and Bi,2008;Han et al.,2008;Jin et al.,2013; Li and Peng,2009; Liu et al.,2009; Li , 2009; Lu,2009; Qi et al., 2008; 
Qin,2006; Yi et al.,2008;Zhang,2008; Yang and Shen,2015; Liu,2015; Lu,2014; Jin,2015). However, our meta-analysis results 
showed that there was no significance in reducing LH levels between treatment with a TCM combined with HT and HT alone 
(Figure 4). 
 
    c. E2 Funnel plot  
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12.9
46.85
35.5
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20.6
36.25
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12.6
10.7
2.03
9.3
15.65
13.7
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6.6
6.6
10.23
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11.28
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26.2
21.82
14.11
9.5
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32.42
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39.32
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27.98
27.36
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Figure 4: Comparisons of treatment efficacy between traditional Chinese medicine combined with hormone therapy and hormone 
therapy alone on LH levels.  
 
E2: All 17 trials included comparisons of the effects on serum E2 levels in patients with POF after using treatment with a TCM 
combined with HT and HT alone(Feng and Li, 2013; Gao and Bi,2008; Han et al.,2008;Jin et al.,2013; Li and Peng,2009; Liu et 
al.,2009; Li , 2009; Lu,2009; Qi et al.,2008; Qin,2006; Yi et al.,2008;Zhang,2008; Zhu and Xie,2012; Yang and Shen,2015; 
Liu,2015; Lu,2014; Jin,2015).The meta-analysis results are shown in Figure 5(Feng and Li, 2013; Gao and Bi,2008; Han et 
al.,2008;Jin et al.,2013; Li and Peng,2009; Liu et al.,2009; Li , 2009; Lu,2009; Qi et al.,2008; Qin,2006; Yi et al.,2008;Zhang,2008; 
Zhu and Xie,2012; Yang and Shen,2015; Liu,2015; Lu,2014; Jin,2015).Treatment with a TCM combined with HT was significantly 
superior compared with that with HT alone for increasing E2 levels (SMD: 3.45, 95% CI: 2.11, 4.79, P < 0.00001). 
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Figure 5: Comparisons of treatment efficacy between traditional Chinese medicine combined with hormone therapy and hormone 
therapy alone on E2 levels. 
 
Perimenopausal Syndrome and Symptom Scores 
 
Three trials compared Kupperman index scores associated with perimenopausal syndrome and symptoms after treatment 
with a TCM combined with HT and HT alone (Feng and Li, 2013; Liu et al., 2009; Yi et al., 2008). Heterogeneity test results 
showed that there was a significant difference between these two treatments (I2=63%, P=0.07); therefore, the effective data were 
combined in a random effects model. The meta-analysis results are shown in Figure 6. The total efficacy showed that therapies with 
a TCM combined with HT were better than those with HT alone for improvements in perimenopausal syndrome and symptoms (-
1.19, 95% CI: -1.77, -0.61, p<0.0001). 
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Figure 6: Comparisons of treatment efficacy between traditional Chinese medicine combined with hormone therapy and hormone 
therapy alone on Kupperman scores. 
 
 
Discussion 
 
POF adversely affects women’s reproductive capacity and the physical health of offspring. POF recently became the focus 
of research(Multidisciplinary Working Group convened by the British Fertility Society,2003; Hudson ,2010; Jolande et al.,2008), 
due to the possibility of preserving the fertility of young women who suffered from cancer during childhood, and reproductive 
technologies in this area are rapidly developing(Wallace et al.,2005).This could have a profound effect on those patients for whom 
premature menopause is suspected (Wallace, 2005). 
Until recently, the most commonly used therapies in Western medicine were difficult to be accepted by patients because of 
the significant side effects and the uncertain efficacy with their long-term use (Liu and Ouyang, 2010). In fact, there are several 
different treatment goals for women with POF, and not all of these apply to all women. The first is fertility for women with POF 
who desire to become pregnant; in this case, “treatment” generally refers to some means to restore ovulatory function and allow for 
conception. For women who do not desire additional childbearing, treatment usually refers to therapies that address a second issue: 
managing their symptoms of estrogen depletion, such as vasomotor symptoms (e.g., hot flashes, sweating, and facial flushing), 
reduced libido, decreased vaginal lubrication, and others. A third issue that applies to all women with POF, but which may receive 
the least amount of attention, is the increased risk of conditions like osteopenia/bone fracture and cardiovascular disease(O'Donnell , 
et al., 2012).Consequently, it is necessary to offer rational strategies for clinical therapies by using alternative methods. 
In TCM theories, although there is no designation “premature ovarian failure,” this can be classified into hypomenorrhea, 
delayed menorrhea, amenorrhea, infertility, early menopause, and others. Dialectical thought and TCM approaches indicate that a 
Chinese herbal medicine can not only maintain homeostasis but also improve the circulation and microcirculation in the body to 
further regulate neuroendocrine function and improve hormone levels based on Chinese dialectical therapy (Yang and Han, 2003). 
Therefore, this therapeutic regime is superior to Western medicine in regulating the neuroendocrine system.  
However, numerous TCM physicians treated diseases based on their experiences; they paid less attention to rigorous design clinical 
researches. Consequently, results in the majority of meta-analysis could not provide for conclusive evidence as well as this review. 
There were several reasons for these. 
Firstly, all studies mentioned that they used randomized allocation; however, only six trials described the methods for random 
sequence generation by using random number tables (Jin et al., 2013; Liu et al., 2009; Yi et al., 2008; Zhang, 2008; Zhu and Xie, 
2012; Yang and Shen, 2015). Only four RCTs described their randomization procedures, although most of these provided only 
incomplete information for which it was difficult to judge whether or not randomization procedures were carried out properly 
comparing with a CONSORT checklist for RCTs. In the other nine trials, “the subjects were randomly distributed into two groups,” 
but without providing any details for how randomization was accomplished. Six of the 17 RCTs used random number tables; 
however, the random allocation was unconcealed, and it was not mentioned whether or not a blinding method was used. We can only 
speculate that it was very difficult to use a blinding method, because of some the characteristics of Chinese medicines, such as aroma, 
color, and appearance, make it easy for patients and doctors to determine which kinds of Chinese herbal medicine they were 
allocated. Only three trials reported on follow-ups, drop-outs, or withdrawals. Consequently, insufficient information was provided 
to judge whether or not these trials were carried out properly. If the methodological approaches were not conducted rigorously, it 
may result in distinct differences between the study and control groups compared with the results of the trials that were performed 
rigorously (Schulz et al., 1995; Moher et al., 2010; Kjaergard et al., 2001; Chand et al., 2010; Beck and Persani, 2006; Chen and Hu, 
2006).This means that the investigators could not appropriately evaluate any therapeutic efficacy. Poor methodology might result in 
biased or invalid results. 
Secondly, syndrome differentiation was applied in the majority of the trials cited. The features and advantage of TCM is using a 
therapy that is based on an individual’s syndrome pattern. In clinical practice with TCM, an herbal prescription must be well-
matched with the symptom type; i.e., “Bianzhenglunzhi,” which is a specific diagnostic approach used in TCM. This method is also 
viewed as a therapy based on an individual’s characteristics, and is considered to be one of the advantages of Chinese medicine. 
However, surprisingly, only two trials provided detailed information on patients’ syndrome differentiation. Almost all practitioners of 
Chinese medicine believe that ineffective treatments may result from failing to perform syndrome differentiation. Ultimately, they 
cannot achieve the desired therapeutic effect or may worsen the disease condition. Thus, authors should be encouraged to explain 
individual syndrome differentiation (Bianzhenglunzhi) using common medical terms so that it is very easily understood or accepted 
by physicians and readers. In addition, unfortunately, because of a lack of placebo controls, the explanation of meaningful results 
using TCM combined with HT therapy requires more rigorous evaluations. 
Thirdly, there was significant heterogeneity in the combined therapies and control interventions between the trials cited, which was 
the major obstacle to estimate their general effects. Because the sources of included studies, the characteristics of subjects, the study 
sites, study designs, diagnostic criteria, interventions, controls, and outcome evaluations were different, there was considerable 
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variation among these studies. It also made it difficult to explore specific factors by using subgroup analyses, and this could certainly 
influence how to judge the effects of these treatments. 
Finally, clinical efficacy was evaluated using four outcome measures, including FSH, LH, and E2 levels and Kupperman scores for 
premenopausal symptoms. These outcome measures were selected because they had good homogeneity, a small publication bias, and 
greater credibility. The patients were diagnosed based on elevated serum FSH levels, which is one criterion to diagnose POF, i.e., 
serum FSH levels > 40 IU/L and amenorrhea ≥6 months (Chand et al. , 2010).Furthermore, POF is associated with decreased E2 
levels and elevated LH levels (Beck and Persani,2006) 
Kupperman index scores are the most commonly used for evaluating menopausal syndrome. In this paper, the results of our meta-
analysis showed that therapies with combined traditional Chinese and Western medicine were better than those with HRT for 
modulating FSH and E2 levels and for improvements in premenopausal syndrome and symptoms, although the LH levels showed 
that there were no significant differences between these two groups. These findings provide preliminary support for the use of 
combined traditional Chinese and Western medicine for treating POF patients.  
         Recently, the World Health Organization advocated evidence-based practices in the field of TCM, because medical decision-
making should follow clinical research methodology (Woad et a1., 2013). A lack of rigorous research evidence contributes to TCM 
facing huge challenges. The results of the present review suggest that the therapeutic efficacy of combined traditional Chinese and 
Western medicine should be strictly evaluated in accordance with the basic criteria for evidence-based medicine, even though 
numerous physicians’ experiences, especially clinical case reporting, have been repeatedly demonstrated for decades（Chen and Hu 
2006）.Both an intention-to-treat analysis and appropriate methods, including dropouts, are important for the design of trials and 
data analysis procedures. Considering that there were insufficient high-quality trials on TCM and HT based on syndrome 
differentiation for treating POF, the proof of the effectiveness of this therapy pattern will need to be confirmed and reevaluated, 
including adequate high-quality trials, large sample sizes, randomized trials, more rigorous placebo-controlled trials, and more 
rigorously designed RCTs.  
 
Conclusions 
 
Although treatment with a combination of TCM and HT was superior to that of HT alone in treating patients with POF, the 
beneficial effects derived from this combination therapy cannot be viewed conclusive. Due to a lack of high-quality trials for treating 
patients with POF to prove the therapeutic effects of the combination therapy, more rigorous trials that conform to the CONSORT 
statement are warranted. A randomization strategy should be used as a standard and described completely and clearly.  
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